Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antipsychotic Agents; Olanzapine; Risperidone

Criteria

Inclusion Criteria:

• Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.

• Patients must have experienced an exacerbation of their illness within the previous 2 weeks.

• Patients in whom a switch to another antipsychotic medication is acutely indicated.

Exclusion Criteria:

• Patients who are deemed nonresponsive to risperidone or olanzapine.

• Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.

• Patients having received olanzapine or risperidone in the past 30 days.

• Treatment with clozapine within 1 year prior to Visit 1.

• Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).

• A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.